广誉远：截至2025年年末，公司原有104个生产批文已全部完成药品再注册

Core Viewpoint - Guangyuyuan reassured investors that its unique product, Gui Ling Ji, is produced and sold in compliance with regulations, and there is no risk of delisting despite the 2025 edition of the Chinese Pharmacopoeia no longer including this product due to the presence of pangolin ingredients [2] Group 1 - The company confirmed that it has completed the revision and approval of the Gui Ling Ji product's instructions in accordance with the new regulations, ensuring that there is no risk of delisting [2] - The company has actively organized and deployed the revision work regarding the new regulations since the issuance of the "Special Regulations on the Registration of Traditional Chinese Medicine" on February 10, 2023 [2] - By the end of 2025, the company will have completed the re-registration of all 104 original production licenses [2]